rs752356873
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_StrongBP6BP7
The NM_032043.3(BRIP1):c.672A>G(p.Gly224Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000112 in 1,613,788 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_032043.3 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152162Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000319 AC: 8AN: 250924Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135612
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461626Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 727106
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152162Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74330
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:3
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
BP4, BP7 c.672A>G, located in exon 7 of the BRIP1 gene, is predicted to result in no amino acid change, p.(Gly224=)(BP7). This variant is found in 3/35090, with a filter allele frequency of 0.001% at 99% confidence in the gnomAD v2.1.1 database (Latino non-cancer data set). The SpliceAI algorithm predicts no significant impact on splicing (BP4). To our knowledge, neither relevant clinical data nor functional studies have been reported for this variant. This variant has been reported in the ClinVar database (1x benign, 5x likely benign) but is not present in LOVD database. Based on currently available information, the variant c.672A>G is classified as a likely benign variant according to ACMG guidelines. -
not provided Uncertain:1Benign:1
Not observed at a significant frequency in large population cohorts (Lek et al., 2016) -
The BRIP1 c.672A>G (p.Gly224=) synonymous variant has not been reported in individuals with BRIP1-related conditions in the published literature. The frequency of this variant in the general population, 0.000087 (3/34574 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant does not affect BRIP1 mRNA splicing. Based on the available information, we are unable to determine the clinical significance of this variant. -
not specified Benign:1
Variant summary: BRIP1 c.672A>G alters a non-conserved nucleotide resulting in a synonymous change. The observed variant frequency within African control individuals in the gnomAD database is approximately 2.08 fold above the estimated maximal expected allele frequency for a pathogenic variant in BRIP1 causing Hereditary Breast and Ovarian Cancer phenotype (6.3e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African origin. To our knowledge, no occurrence of c.672A>G in individuals affected with Hereditary Breast and Ovarian Cancer and no experimental evidence demonstrating its impact on protein function have been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign. -
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Benign:1
- -
Familial cancer of breast Benign:1
This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at